Feb 13 (Reuters) - Lonza Group AG:
* EMERALD HEALTH PHARMACEUTICALS AND LONZA ANNOUNCE AGREEMENT FOR MANUFACTURING OF NOVEL CANNABINOID-DERIVED DRUG CANDIDATE
* PATENTED NEW CHEMICAL ENTITY DERIVED FROM SYNTHETIC CANNABIDIOL WILL INITIALLY TARGET MULTIPLE SCLEROSIS AND SCLERODERMA
* END-TO-END SOLUTION FOR PROCESS DEVELOPMENT AND MANUFACTURING OF API AND DOSAGE FORM WILL FACILITATE THE ADVANCEMENT OF CLINICAL DEVELOPMENT
* AGREEMENT WILL DEVELOP CGMP-STANDARD DRUG PRODUCT IN FORMATS THAT ARE EASY FOR PATIENTS TO TAKE Source text: bit.ly/2TN0lab Further company coverage: (Reporting by Berlin Speed Desk)
Our Standards:The Thomson Reuters Trust Principles.
Read Again https://www.reuters.com/article/brief-emerald-lonza-to-manufacture-canna/brief-emerald-lonza-to-manufacture-cannabinoid-derived-drug-candidate-idUSFWN2080LW
Bagikan Berita Ini
Related Posts :
Laptop manufacturing: Import nods likely to be linked to local capacity - The Indian Express- 250 people to be laid off by Loudon County manufacture - WATE 6 On Your Side
- Taiwan struggles to reconcile climate ambitions and chip manufacturing - Al Jazeera English
- For over $11 billion, Lockheed Martin will manufacture 145 new F-35 fighters for the U.S. Armed Forces and its allies - Zona Militar
- A U.S. manufacturing renaissance is not that easy - Salon
0 Response to "BRIEF-Emerald, Lonza To Manufacture Cannabinoid-Derived Drug Candidate - Reuters"
Post a Comment